Covid 19 coronavirus: Events sector seeks fair go treatment with big malls during level 2 responses
6 Apr, 2021 05:28 AM
3 minutes to read
The $5 billion a year exhibition industry, which includes events like the Hutch Wilco New Zealand Boat Show, has been hit hard by Covid. Photo / File
The $5 billion a year exhibition industry, which includes events like the Hutch Wilco New Zealand Boat Show, has been hit hard by Covid. Photo / File
The $5 billion a year exhibition industry, on its knees due to Covid-19 restrictions, has petitioned the Government for events to have the same opening rights as mega-malls have during level 2 lockdowns.
Spectrum Health s cloud-based SCM platform adds performance and resilience to its clinically aligned supply chain operations.
GRAND RAPIDS, Mich., April 5, 2021 /PRNewswire/ Â Tecsys Inc. (TSX: TCS), an industry-leading supply chain management software company, is pleased to announce that Spectrum Health, western Michigan s largest employer and one of the Gartner Top 25 Healthcare Supply Chains for three years running, has upgraded its Tecsys environment to accommodate its growing network of supply chain and warehousing demands. The new ecosystem includes a SaaS supply chain management platform with distribution management, warehouse management and delivery management, with robust connectors to Spectrum Health s Workday ERP.
Spectrum Health is a not-for-profit award-winning $8 billion integrated health system comprised of 14 hospitals and 150 ambulatory sites. Its supply chain organization services a diverse network of hospitals, treatment facilities, outpatient centers and urge
MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE)
Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Company, with effect 24 June 2021. Opthea has initiated a search for a permanent replacement with requisite expertise in financial reporting and company secretarial duties for a dual ASX and Nasdaq listed company.
Mr Tonroe leaves Opthea at a time of corporate growth and emerging presence in the US to align with the recent listing on Nasdaq and initiation of the Company’s global Phase 3 clinical development program for OPT-302 in wet age-related macular degeneration (wet AMD).
Published: Apr 02, 2021
SAN DIEGO, Calif., April 2, 2021 /PRNewswire/ Together with scientists from the University of California, San Diego (UCSD), Global Cancer Technology (GCT) and the renowned Barrow Neurological Institute, pre-clinical studies have begun towards the commercialization of a new glioblastoma treatment. Glioblastoma is a rare cancer, occurring in fewer than one in 10,000 cases; however, it is among the most aggressive and lethal cancers. Fewer than 25% of those diagnosed will survive one year and fewer than 5% survive five years. Incidence in men is slightly higher than in women with the average age of diagnosis around 60. Glioblastoma is on the rise where contributing factors including ionizing radiation, air pollution, and an aging population. Each year, more than 17,000 Americans die from this incurable disease.